These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38976823)

  • 1. Deciphering the Thermal Stability of Bacteriophage MS2-Derived Virus-like Particle and Its Engineered Variant.
    Vishwakarma P; Puri S; Banerjee M; Chang CY; Chang CC; Chaudhuri TK
    ACS Biomater Sci Eng; 2024 Aug; 10(8):4812-4822. PubMed ID: 38976823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Effects of Intersubunit Interface Mutations on Virus-Like Particle Structure and Stability.
    Pistono PE; Xu J; Huang P; Fetzer JL; Francis MB
    Biochemistry; 2024 Aug; 63(15):1913-1924. PubMed ID: 39037053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform.
    Galaway FA; Stockley PG
    Mol Pharm; 2013 Jan; 10(1):59-68. PubMed ID: 23110441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Surface Modification of Genome-Free MS2 Capsids for Delivery Applications.
    Aanei IL; Francis MB
    Methods Mol Biol; 2018; 1776():629-642. PubMed ID: 29869270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative characterization of all single amino acid variants of a viral capsid-based drug delivery vehicle.
    Hartman EC; Jakobson CM; Favor AH; Lobba MJ; Álvarez-Benedicto E; Francis MB; Tullman-Ercek D
    Nat Commun; 2018 Apr; 9(1):1385. PubMed ID: 29643335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the role of protein-protein and protein-nucleic acid interactions in MS2 bacteriophage stability.
    Lima SM; Vaz AC; Souza TL; Peabody DS; Silva JL; Oliveira AC
    FEBS J; 2006 Apr; 273(7):1463-75. PubMed ID: 16689932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
    Ashley CE; Carnes EC; Phillips GK; Durfee PN; Buley MD; Lino CA; Padilla DP; Phillips B; Carter MB; Willman CL; Brinker CJ; Caldeira Jdo C; Chackerian B; Wharton W; Peabody DS
    ACS Nano; 2011 Jul; 5(7):5729-45. PubMed ID: 21615170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of bacteriophage phiCb5 reveals a role of the RNA genome and metal ions in particle stability and assembly.
    Plevka P; Kazaks A; Voronkova T; Kotelovica S; Dishlers A; Liljas L; Tars K
    J Mol Biol; 2009 Aug; 391(3):635-47. PubMed ID: 19559027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.
    Peabody DS; Manifold-Wheeler B; Medford A; Jordan SK; do Carmo Caldeira J; Chackerian B
    J Mol Biol; 2008 Jun; 380(1):252-63. PubMed ID: 18508079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
    Legendre D; Fastrez J
    J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurements of the self-assembly kinetics of individual viral capsids around their RNA genome.
    Garmann RF; Goldfain AM; Manoharan VN
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22485-22490. PubMed ID: 31570619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.
    Mikel P; Vasickova P; Kralik P
    Sci Rep; 2017 Dec; 7(1):17501. PubMed ID: 29235545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.
    Naskalska A; Heddle JG
    Nanomedicine (Lond); 2024; 19(12):1103-1115. PubMed ID: 38629576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles.
    Pan Y; Zhang Y; Jia T; Zhang K; Li J; Wang L
    FEBS J; 2012 Apr; 279(7):1198-208. PubMed ID: 22309233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel delivery platform based on Bacteriophage MS2 virus-like particles.
    Fu Y; Li J
    Virus Res; 2016 Jan; 211():9-16. PubMed ID: 26415756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The three-dimensional structure of genomic RNA in bacteriophage MS2: implications for assembly.
    Toropova K; Basnak G; Twarock R; Stockley PG; Ranson NA
    J Mol Biol; 2008 Jan; 375(3):824-36. PubMed ID: 18048058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection.
    Adeyemi OO; Nicol C; Stonehouse NJ; Rowlands DJ
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
    Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
    Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preparation and Characterization of Recombinant HEV RNA-loaded MS2 Bacteriophage Capsid by Armored RNA Technology].
    Liu Y; Wang S; Zhou T; Gao S
    Bing Du Xue Bao; 2016 Sep; 32(5):538-44. PubMed ID: 30001574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.